Transcode Therapeutics Files 8-K
Ticker: RNAZ · Form: 8-K · Filed: Feb 4, 2025 · CIK: 1829635
Sentiment: neutral
Topics: corporate-disclosure, regulatory-filing
TL;DR
Transcode Therapeutics filed an 8-K on Feb 4, 2025, covering votes, other events, and financials.
AI Summary
Transcode Therapeutics, Inc. filed an 8-K on February 4, 2025, reporting on matters submitted to a vote of security holders, other events, and financial statements/exhibits. The filing does not detail specific votes, events, or financial figures but serves as a notification of these items.
Why It Matters
This filing indicates that Transcode Therapeutics has submitted matters for a vote and is providing updates on other events and financial information, which are crucial for investors to monitor company activities.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not contain specific negative or positive news that would immediately impact risk.
Key Players & Entities
- Transcode Therapeutics, Inc. (company) — Registrant
- February 4, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40363 (company_id) — SEC File Number
- 81-1065054 (company_id) — I.R.S. Employer Identification No.
- 6 Liberty Square, #2382 Boston, Massachusetts 02109 (address) — Principal executive offices
- ( 857 ) 837-3099 (phone_number) — Registrant's telephone number
FAQ
What specific matters were submitted to a vote of Transcode Therapeutics' security holders?
The filing does not specify the exact matters submitted to a vote, only that such submissions occurred.
What were the 'Other Events' reported by Transcode Therapeutics on February 4, 2025?
The filing indicates that 'Other Events' were reported but does not provide details on what those events were.
Does this 8-K filing include detailed financial statements for Transcode Therapeutics?
The filing lists 'Financial Statements and Exhibits' as an item, but the provided text does not contain the actual financial statements or their details.
What is the principal business of Transcode Therapeutics, Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code provided is 2834, which corresponds to Pharmaceutical Preparations.
Where are Transcode Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 6 Liberty Square, #2382, Boston, Massachusetts 02109.
Filing Stats: 890 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2025-02-04 16:20:21
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share RNAZ The Nasdaq Capital M
- $0 — f the Company's common stock, par value $0.0001, present or represented by proxy a
Filing Documents
- tm255410d1_8k.htm (8-K) — 29KB
- tm255410d1_ex99-1.htm (EX-99.1) — 19KB
- tm255410d1_ex99-1img001.jpg (GRAPHIC) — 13KB
- 0001104659-25-009122.txt ( ) — 244KB
- rnaz-20250204.xsd (EX-101.SCH) — 3KB
- rnaz-20250204_lab.xml (EX-101.LAB) — 33KB
- rnaz-20250204_pre.xml (EX-101.PRE) — 22KB
- tm255410d1_8k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference.
01 Other Events
Item 8.01 Other Events. On February 4, 2025, TransCode Therapeutics, Inc. (the "Company") convened a special meeting of stockholders (the "Special Meeting") to vote upon the proposals set forth in the definitive proxy statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on December 30, 2024 (the "Proxy Statement"). There were 156,675 shares of the Company's common stock, par value $0.0001, present or represented by proxy at the Special Meeting, which did not constitute a quorum under the Company's bylaws. Accordingly, the Special Meeting was adjourned without any business being conducted in order to allow time to achieve a quorum and to allow the Company's stockholders additional time to vote on the proposals described in the Proxy Statement. Accordingly, the Special Meeting was adjourned and as announced at the Special Meeting, such meeting will reconvene again at 9:30 a.m. Eastern Time on February 25, 2025, virtually at www.virtualshareholdermeeting.com/RNAZ2025SM. During the period of adjournment, the Company will continue to solicit stockholder votes. The record date for the determination of stockholders of the Company entitled to vote at the adjourned Special Meeting remains the close of business on December 17, 2024. On February 4, 2025, the Company issued a press release announcing that it had adjourned the Special Meeting. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated by reference. Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as "believe," "can," "could," "design," "estimate," "expect," "intend," "may," "might," "objective," "plan" "potential," "predict," "should," "will," "would," or the negative of these
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Exhibit Description 99.1 Press Release, dated February 4, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TransCode Therapeutics, Inc. Date: February 4, 2025 By: /s/ Thomas A. Fitzgerald Thomas A. Fitzgerald Interim Chief Executive Officer; Chief Financial Officer